Testing Blood Samples to Find Pancreatic Cancer Early
Studies blood tests to detect pancreatic cancer early and track treatment response in adults.
Plain-language title generated from the registry record
Registry title: A Study of Blood Based Biomarkers for Pancreas Adenocarcinoma
Key facts
- Where
- Jerusalem, Rehovot, and Tel HaShomer, IsraelSee the 3 sites
Where in Israel
- Sha'are Zedek Medical CenterJerusalem, IsraelNot yet recruiting
- Weizmann Institute of ScienceRehovot, IsraelNot yet recruiting
- Sheba medical centerTel HaShomer, IsraelTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Memorial Sloan Kettering Cancer Center
- Trial code
- NCT03334708
- Record updated
- 14 August 2026
- Original description
The purpose of this study is to develop a minimally invasive test to diagnose pancreatic cancer at early stages of disease and monitor response to treatment.Read full original descriptionShow less
Development of Biomarkers for the Early Detection, Surveillance and Monitoring of Pancreatic Ductal Adenocarcinoma
The purpose of this study is to develop a minimally invasive test to diagnose pancreatic cancer at early stages of disease and monitor response to treatment.
Inclusion: Cohort 1: Advanced Pancreatic Cancer Cohort Inclusion Criteria; Radiological, histological or cytological confirmed diagnosis of locally advanced or metastatic pancreatic adenocarcinoma by the enrolling institution; Patient planning to receive systemic treatment; Hemoglobin > 8; ECOG performance status 0-2; A minimum age of 18 years old; Willing to provide permission to obtain banked tumor tissue for analysis (previous biopsies or surgical material); Cohort 2: Operable Pancreatic Cancer Cohort Inclusion Criteria; Radiological, histological or cytological confirmed diagnosis of pancreatic adenocarcinoma by the enrolling institution; Patient planned to undergo upfront resection; No pre-operative systemic therapy nor chemoradiation therapy planned; Hemoglobin > 8; ECOG performance status 0-2; A minimum age of 18 years old; Willing to provide permission to obtain banked tumor tissue for analysis (previous biopsies or surgical material); Cohort 3: Acute Benign Pancreatic Pathology Control Inclusion Criteria; Confirmed diagnosis of acute pancreatitis or other acute pancreatic pathology by the enrolling institution; Hemoglobin > 8; ECOG performance status 0-2; A minimum age of 18 years old; Cohort 4: Chronic Benign Pancreatic Pathology Control Inclusion Criteria; Confirmed diagnosis of chronic pancreatitis or other non-cystic chronic pancreatic pathology by the enrolling institution; Hemoglobin > 8; ECOG performance status 0-2; A minimum age of 18 years old; Cohort 5: IPMN Control Inclusion Criteria; Confirmed diagnosis of IPMN without high risk features by the enrolling institution; A minimum age of 18 years old; Cohort 6: Pancreatic Cyst Control Inclusion Criteria; Confirmed diagnosis of benign pancreatic cyst by the enrolling institution; A minimum age of 18 years old; Cohort 7: Healthy Control Inclusion Criteria; A minimum age of 18 years old.
Exclusion: Prior chemotherapy or radiation therapy for pancreatic cancer within the last 3 months in the localized setting; Neoadjuvant chemotherapy or radiation therapy is planned; IPMN with high risk features or planned resection; Cohort 1: Advanced Pancreatic Cancer Cohort Exclusion Criteria; Active second malignancy, unless low grade malignancy; Any medical or psychiatric condition that may interfere with ability to comply with protocol procedures; Cohort 2: Operable Pancreatic Cancer Cohort Exclusion Criteria; Active second malignancy, unless low grade malignancy; Any medical or psychiatric condition that may interfere with ability to comply with protocol procedures; Cohort 3: Acute Benign Pancreatic Pathology Control Exclusion Criteria; Active or prior malignancy, except prior non-melanoma skin cancer; Proven to be a carrier of a cancer susceptibility gene or family history concerning for genetic predisposition to cancer; Any medical or psychiatric condition that may interfere with ability to comply with protocol procedures; Cohort 4: Chronic Benign Pancreatic Pathology Control Exclusion Criteria; Active or prior malignancy, except prior non-melanoma skin cancer; Proven to be a carrier of a cancer susceptibility gene or family history concerning for genetic predisposition to cancer; Any medical or psychiatric condition that may interfere with ability to comply with protocol procedures; Cohort 5: IPMN Control Exclusion Criteria; Active or prior malignancy, except prior non-melanoma skin cancer; Proven to be a carrier of a cancer susceptibility gene or family history concerning for genetic predisposition to cancer; Any medical or psychiatric condition that may interfere with ability to comply with protocol procedures; Cohort 6: Pancreatic Cyst Control Exclusion Criteria; Active or prior malignancy, except prior non-melanoma skin cancer; Proven to be a carrier of a cancer susceptibility gene or family history concerning for genetic predisposition to cancer; Any medical or psychiatric condition that may interfere with ability to comply with protocol procedures; Cohort 7: Healthy Control Exclusion Criteria; Active or prior malignancy, except prior non-melanoma skin cancer; Proven to be a carrier of a cancer susceptibility gene or family history concerning for genetic predisposition to cancer; Any medical or psychiatric condition that may interfere with ability to comply with protocol procedures.